Intracellular indinavir pharmacokinetics in HIV-infected patients: Comparison with plasma pharmacokinetics

Antiviral Therapy

Volumn 8, Issue 3, 2003, Pages 191-198

  Hennessy, Martina ^a   Clarke, Susan ^b   Spiers, J Poul ^a   Mulcahy, Fiona ^b   Kelleher, Dermot ^a   Meadon, Emma ^c   Maher, Bridget ^c   Bergin, Colm ^b   Khoo, Saye ^c   Tjia, John ^c   Hoggard, Patrick ^c   Back, David ^c   Barry, Michael ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DENSITY GRADIENT CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; INTRACELLULAR SPACE; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0043157305     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Coffin JM. Retroviridae and their replication. In: Fields Virology. Edited by B Fields. 1991; 645-708, Raven Press: New York.
2. Dreyer GB, Metcalf BW, Tomaszek TA, Carr TJ, Chandler ACD, Hyland L, Fakhoury SA, Magaard VW, Moore ML & Strickler JE. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proceedings of the National Academy of Sciences, USA 1989; 86:9752-9756.
3. Debouck C. The HIV 1 protease as a therapeutic target for AIDS. AIDS Research & Human Retroviruses 1992; 8:153-164.
4. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
5. Ledergerber B, Egger M, Opravil M, Telenti A, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P & Weber R for the Swis HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
6. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
7. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W & Hekster YA. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998; 3:215-220.
8. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M & Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 1999; 179:1116-1123.
9. Acosta EP, Henry K, Baken L, Page LM & Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19:708-712.
10. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000; 283:205-211.
11. Harris M, Durakovic C, Rae S, Raboud J, Fransen S, Shillington A, Conway B & Montaner JSG. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. Journal of Infections Diseases 1998; 177:1514-1520.
12. Back DJ, Khoo SH, Gibbons SE & Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. British Journal of Clinical Pharmacology 2001; 51:301-308.
13. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, & Merigan TC. The effect of high dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Annals of Internal Medicine 1996; 124:1039-1050.
14. Burger DM, de Graaf M, Wuis EW, Koopmans PP & Hekster YA. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reverse-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences & Applications 1997; 703:235-241.
15. Burger DM, Hugen PWH, Draste J & Huitema A. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. 1st International Conference on HIV Pathogenesis & Treatment, Buenos Aries 2001. Abstract 30.
16. Casado JL, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, Perez-Elias MJ, Moreno A & NELSANE study. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 2002; 16:47-52.
17. Zhang L, Ramaratam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M & Ho DD. Quantifying residual HIV-1 replication receiving combination antiretroviral therapy. New England Journal of Medicine 1999; 340:1605-1613.
18. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
19. Hotelmans RM. Sanctuary sites in HIV-1 infection. Antiviral Therapy 1998; 3:13-17.
20. Profit L, Eagling VA & Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13:1623-1627.
21. Clayette P, Jorjuria S & Dormont D. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14:235-236.
22. Huisman T, Smit JW & Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14:237-242.
23. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang K-T, Ambudkar SV, Pastan I & Dey S. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochemistry 1998; 37:3594-3601.
24. Freed EO & Martin MA. HIVs and their replication. In: Fields Virology. Edited by BN Fields, DM Knipe & PM Howley. 1996; 1971-2026, New York: Raven Press.
25. Erickson J, Neldhart D, VanDrie J, Kempf D, Wang X, Norbeck D, Plattner J, Rittenhouse J, Turon M, Wildeburg N, Kohlbrenner W, Simmer R, Helfrick R, Paul D & Knigge M. Design, activity, and 2.8A crystal structue of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249:527-533.
26. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R & Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrobial Agents & Chemotherapy 2000; 43:2629-2634.
27. Jones K, Hoggard P, Sales SD, Khoo SH, Davey R & Back D. Differences in intracellular accumulation of HIV protease Inhibitors in vitro and the effect of active transport. AIDS 2001; 15:675-681.
28. Barry MG, Merry C, Lloyd J, Halifax K, Carey P, Mulcahy F & Back DJ. Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring. British Journal of Clinical Pharmacology 1998; 45:501-502.
29. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S & Richman DD for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. Journal of the American Medical Association 1998; 279:1984-1991.
30. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A & Leonard JM. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-F14.
31. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA & Back DJ. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001; 15:1353-1358.
32. Rayner CR, Galbraith KJ, Marriott JL & Duncan GJ. A critical evaluation of the therapeutic range of indinavir. Annals of Pharmacotherapy 2002; 36:1230-1237.
33. Lee CG & Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. Journal of Clinical Investigation 1998; 101:287-288.